Research programme: recombinant human alpha-1 antitrypsin - rEVO Biologics

Drug Profile

Research programme: recombinant human alpha-1 antitrypsin - rEVO Biologics

Alternative Names: AAT - GTC; Alpha-1 proteinase inhibitor - GTC; Alpha-1-antitrypsin - GTC; rhAAT - GTC; TgAAT - GTC

Latest Information Update: 21 Feb 2013

Price : $50

At a glance

  • Originator GTC Biotherapeutics; LFB Biotechnologies
  • Developer rEVO Biologics
  • Class Acute-phase proteins; Alpha globulins; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
  • Mechanism of Action Pancreatic elastase inhibitors; Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • Available For Licensing Yes - Alpha 1-antitrypsin deficiency

Highest Development Phases

  • Preclinical Alpha 1-antitrypsin deficiency

Most Recent Events

  • 04 Jan 2013 GTC Biotherapeutics is now called rEVO Biologics
  • 07 Dec 2010 GTC Biotherapeutics has been acquired by LFB Biotechnologies
  • 31 Dec 2009 Alpha-1 antitrypsin is available for licensing (http://www.gtc-bio.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top